Retroviral vectors. From laboratory tools to molecular medicine.
The majority of clinical trials for gene therapy currently employ retroviral-mediated gene delivery. This is because the life cycle of the retrovirus is well understood and can be effectively manipulated to generate vectors that can be efficiently and safely packaged. Here, we review the molecular technology behind the generation of recombinant retroviral vectors. We also highlight the problems associated with the use of these viruses as gene therapy vehicles and discuss future developments that will be necessary to maintain retroviral vectors at the forefront of gene transfer technology.
Vile
R G
RG
Imperial Cancer Research Fund Laboratory of Cancer Gene Therapy, Rayne Institute, St Thomas' Hospital, London.
Tuszynski
A
A
Castleden
S
S
D000818:Animals; D002986:Clinical Trials as Topic; D005544:Forecasting; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D012190:Retroviridae / Q000145:classification / Q000235:genetics / Q000648:ultrastructure